Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update

Area of Science:

• Uro-oncology
• Medical oncology
• Immunotherapy

Background:

• Upper tract urothelial carcinoma (UTUC) comprises 5-10% of urothelial carcinoma (UC) cases.
• Many UTUC patients require systemic treatment due to advanced presentation or aggressive disease.
• Limited data and evolving treatment strategies complicate UTUC management, especially in perioperative and metastatic settings.

Purpose of the Study:

• To review the current role of immunotherapy in locally advanced and metastatic UTUC.
• To outline the safety profile of immunotherapy regimens in UTUC.

Main Methods:

• Literature review of immunotherapy in upper tract urothelial carcinoma.
• Analysis of approved immunotherapy agents for metastatic UC.
• Summary of safety data for immunotherapy in UTUC.

Main Results:

• Several PD-1/PD-L1 inhibitors are approved for second-line metastatic UTUC treatment.
• First-line immunotherapy is approved for cisplatin-ineligible UTUC patients with PD-L1 positive tumors.
• The safety profile of these immunotherapies in UTUC is being established.

Conclusions:

• Immunotherapy plays a crucial role in both first-line and second-line treatment of advanced UTUC.
• Ongoing research is vital to further define the optimal use and safety of immunotherapy in UTUC.
• The evolving landscape of UTUC treatment increasingly incorporates immunotherapeutic approaches.